254 related articles for article (PubMed ID: 22159600)
1. Profilin 1 is a potential biomarker for bladder cancer aggressiveness.
Zoidakis J; Makridakis M; Zerefos PG; Bitsika V; Esteban S; Frantzi M; Stravodimos K; Anagnou NP; Roubelakis MG; Sanchez-Carbayo M; Vlahou A
Mol Cell Proteomics; 2012 Apr; 11(4):M111.009449. PubMed ID: 22159600
[TBL] [Abstract][Full Text] [Related]
2. IMAC fractionation in combination with LC-MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers.
Frantzi M; Zoidakis J; Papadopoulos T; Zürbig P; Katafigiotis I; Stravodimos K; Lazaris A; Giannopoulou I; Ploumidis A; Mischak H; Mullen W; Vlahou A
J Proteome Res; 2013 Sep; 12(9):3969-79. PubMed ID: 23924207
[TBL] [Abstract][Full Text] [Related]
3. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
[TBL] [Abstract][Full Text] [Related]
4. Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer.
Chen CL; Chung T; Wu CC; Ng KF; Yu JS; Tsai CH; Chang YS; Liang Y; Tsui KH; Chen YT
Mol Cell Proteomics; 2015 Sep; 14(9):2466-78. PubMed ID: 26081836
[TBL] [Abstract][Full Text] [Related]
5. Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer models.
Frantzi M; Klimou Z; Makridakis M; Zoidakis J; Latosinska A; Borràs DM; Janssen B; Giannopoulou I; Lygirou V; Lazaris AC; Anagnou NP; Mischak H; Roubelakis MG; Vlahou A
Oncotarget; 2016 Oct; 7(43):70750-70768. PubMed ID: 27683119
[TBL] [Abstract][Full Text] [Related]
6. Far from resolved: stromal cell-based iTRAQ research of muscle-invasive bladder cancer regarding heterogeneity.
Liu PF; Wang YH; Cao YW; Jiang HP; Yang XC; Wang XS; Niu HT
Oncol Rep; 2014 Oct; 32(4):1489-96. PubMed ID: 25050759
[TBL] [Abstract][Full Text] [Related]
7. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer.
Lindén M; Lind SB; Mayrhofer C; Segersten U; Wester K; Lyutvinskiy Y; Zubarev R; Malmström PU; Pettersson U
Proteomics; 2012 Jan; 12(1):135-44. PubMed ID: 22065568
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Evaluation of Urine from Patients Diagnosed with High Grade (HG) Bladder Cancer by SPME-LC-MS Method.
Łuczykowski K; Warmuzińska N; Operacz S; Stryjak I; Bogusiewicz J; Jacyna J; Wawrzyniak R; Struck-Lewicka W; Markuszewski MJ; Bojko B
Molecules; 2021 Apr; 26(8):. PubMed ID: 33920347
[TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Investigation toward the Indicative Proteins of Bladder Cancer in Urine: From Surveying Cell Secretomes to Verifying Urine Proteins.
Guo J; Ren Y; Hou G; Wen B; Xian F; Chen Z; Cui P; Xie Y; Zi J; Lin L; Wu S; Li Z; Wu L; Lou X; Liu S
J Proteome Res; 2016 Jul; 15(7):2164-77. PubMed ID: 27265680
[TBL] [Abstract][Full Text] [Related]
11. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.
Hermanns T; Savio AJ; Olkhov-Mitsel E; Mari A; Wettstein MS; Saba K; Bhindi B; Kuk C; Poyet C; Wild PJ; Noon A; Bashir S; Juvet T; Rendon RA; Waltregny D; van der Kwast T; Finelli A; Kulkarni GS; Fleshner NE; Lo K; Bapat B; Zlotta AR
Urol Oncol; 2020 Jun; 38(6):603.e1-603.e7. PubMed ID: 32081560
[TBL] [Abstract][Full Text] [Related]
12. A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness.
Grau L; Luque-Garcia JL; González-Peramato P; Theodorescu D; Palou J; Fernandez-Gomez JM; Sánchez-Carbayo M
PLoS One; 2013; 8(1):e53328. PubMed ID: 23308193
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of urinary and tissue-exudative extracellular vesicles to discover novel bladder cancer biomarkers.
Tomiyama E; Matsuzaki K; Fujita K; Shiromizu T; Narumi R; Jingushi K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Takao T; Adachi J; Tomonaga T; Nonomura N
Cancer Sci; 2021 May; 112(5):2033-2045. PubMed ID: 33721374
[TBL] [Abstract][Full Text] [Related]
14. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
[TBL] [Abstract][Full Text] [Related]
15. Individual risk assessment in bladder cancer patients based on a multi-marker panel.
Todenhöfer T; Hennenlotter J; Aufderklamm S; Kühs U; Gakis G; Germann M; Stenzl A; Schwentner C
J Cancer Res Clin Oncol; 2013 Jan; 139(1):49-56. PubMed ID: 22893018
[TBL] [Abstract][Full Text] [Related]
16. Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics.
Chen CL; Lin TS; Tsai CH; Wu CC; Chung T; Chien KY; Wu M; Chang YS; Yu JS; Chen YT
J Proteomics; 2013 Jun; 85():28-43. PubMed ID: 23631828
[TBL] [Abstract][Full Text] [Related]
17. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach.
Huang Z; Lin L; Gao Y; Chen Y; Yan X; Xing J; Hang W
Mol Cell Proteomics; 2011 Oct; 10(10):M111.007922. PubMed ID: 21799048
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
19. Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis.
Eissa S; Matboli M; Essawy NO; Kotb YM
Tumour Biol; 2015 Dec; 36(12):9545-52. PubMed ID: 26138586
[TBL] [Abstract][Full Text] [Related]
20. Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer.
Azevedo R; Soares J; Gaiteiro C; Peixoto A; Lima L; Ferreira D; Relvas-Santos M; Fernandes E; Tavares A; Cotton S; Daniel-da-Silva AL; Santos LL; Vitorino R; Amado F; Ferreira JA
Talanta; 2018 Jul; 184():347-355. PubMed ID: 29674052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
